Acrivon Therapeutics (ACRV) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Acrivon Therapeutics will report Q1 2026 results before the market opens on May 13, 2026; analysts forecast EPS of ($0.49) and revenue of about $0.277M, with an earnings call scheduled for May 15, 2026 at 4:00 PM ET.
• The stock opened at $2.08 and was trading down roughly 4.1%, while Wall Street consensus rates ACRV a "Moderate Buy" with an average target price of $11.67, implying significant upside from current levels.
• Acrivon is a clinical‑stage biotech developing hydrocarbon‑stapled peptide therapeutics, with a lead candidate targeting the KRAS G12C mutation currently in early clinical trials.

Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) will likely be issuing its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Acrivon Therapeutics to post earnings of ($0.49) per share and revenue of $0.2770 million for the quarter. Investors are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) last posted its quarterly earnings data on Thursday, March 19th. The company reported ($0.49) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.49). On average, analysts expect Acrivon Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Acrivon Therapeutics Trading Down 4.1%

Shares of NASDAQ ACRV opened at $2.08 on Wednesday. The stock has a market cap of $89.02 million, a P/E ratio of -1.03 and a beta of 2.01. The business's fifty day simple moving average is $1.64 and its 200-day simple moving average is $1.94. Acrivon Therapeutics has a 12-month low of $1.05 and a 12-month high of $3.56.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Piper Sandler upped their price target on Acrivon Therapeutics from $6.00 to $8.00 and gave the stock an "overweight" rating in a report on Friday, January 9th. Wall Street Zen cut Acrivon Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday, March 1st. Jefferies Financial Group restated a "buy" rating on shares of Acrivon Therapeutics in a research note on Monday, March 2nd. Finally, Weiss Ratings raised shares of Acrivon Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, April 27th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $11.67.

Hedge Funds Weigh In On Acrivon Therapeutics

Several large investors have recently bought and sold shares of ACRV. UBS Group AG boosted its position in shares of Acrivon Therapeutics by 150,057.8% during the 3rd quarter. UBS Group AG now owns 683,218 shares of the company's stock worth $1,237,000 after acquiring an additional 682,763 shares in the last quarter. Marshall Wace LLP raised its position in shares of Acrivon Therapeutics by 231.4% during the 4th quarter. Marshall Wace LLP now owns 496,081 shares of the company's stock worth $1,196,000 after acquiring an additional 346,366 shares in the last quarter. Jane Street Group LLC purchased a new stake in Acrivon Therapeutics during the second quarter worth approximately $371,000. Two Sigma Investments LP lifted its stake in Acrivon Therapeutics by 76.2% during the third quarter. Two Sigma Investments LP now owns 319,205 shares of the company's stock worth $578,000 after purchasing an additional 138,033 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in Acrivon Therapeutics in the second quarter valued at approximately $126,000. Hedge funds and other institutional investors own 71.62% of the company's stock.

About Acrivon Therapeutics

Acrivon Therapeutics NASDAQ: ACRV is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company's lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.